Syros PharmaceuticalsSYRS
13F holders, Q4 2024 (December 31)44holders −21
7new positions
29sold out
1famous investor
$0.23avg. 13F price*
At the end of Q4 2024, 44 institutions reported holding Syros Pharmaceuticals Inc. (SYRS) in their 13F filings, down 21 from Q3 2024. 7 opened new positions and 29 sold out. The largest holders were Bain Capital Life Sciences Investors, LLC ($632K), BlackRock, Inc. ($64K) and Vanguard Group Inc. ($62K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Syros Pharmaceuticals Inc.
- CUSIP
- 87184Q206
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $97K |
| Exits | 29 | $30.0M |
All 13F filers, Q3 2024 → Q4 2024: 942,507 shares bought and 14,666,041 shares sold, net −13,723,534 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 44 holders
| Bain Capital Life Sciences Investors, LLC | 0.07% | No change | 2,750,151 | $632K |
| BlackRock, Inc. | 0.00% | Add +6.0% | 277,253 | $64K |
| Vanguard Group Inc. | 0.00% | Reduce -71.9% | 268,154 | $62K |
| Omega Fund Management, LLC | 0.04% | No change | 251,270 | $58K |
| Acadian Asset Management LLC | 0.00% | Add +371.8% | 249,426 | $55K |
| Geode Capital Management, LLC | 0.00% | Reduce -4.1% | 196,252 | $45K |
| Affinity Asset Advisors, LLC | 0.01% | New | 150,000 | $34K |
| Citigroup Inc. | 0.00% | Add +20165.5% | 139,224 | $32K |
| Qube Research & Technologies Ltd | 0.00% | Add +57.2% | 122,174 | $28K |
| Two Sigma Securities, LLC | 0.00% | New | 107,742 | $25K |
| Renaissance Technologies | 0.00% | Reduce -0.4% | 96,042 | $22K |
| HRT Financial LP | 0.00% | New | 87,535 | $20K |
| XTX Topco Ltd | 0.00% | Add +182.5% | 81,460 | $19K |
| State Street Corp. | 0.00% | No change | 69,430 | $16K |
| Jane Street Group, LLC | 0.00% | New | 52,920 | $12K |
| Two Sigma Investments, LP | 0.00% | Add +71.6% | 48,861 | $11K |
| UBS Group AG | 0.00% | Add +169.3% | 45,050 | $10K |
| Northern Trust Corp. | 0.00% | No change | 40,812 | $9K |
| 1492 Capital Management LLC | 0.00% | No change | 39,244 | $9K |
| Virtu Financial LLC | 0.00% | Add +67.0% | 32,791 | $8K |
| Baader Bank Aktiengesellschaft | 0.00% | New | 22,092 | $5K |
| Clarius Group, LLC | 0.00% | No change | 18,620 | $4K |
| Marex Group Ltd | 0.00% | Add +31.5% | 16,700 | $4K |
| HighTower Advisors, LLC | 0.00% | No change | 14,898 | $3K |
| Corient Private Wealth LP | 0.00% | No change | 12,000 | $3K |
| Aster Capital Management (DIFC) Ltd | 0.00% | No change | 9,970 | $2K |
| Centerpoint Advisors, LLC | 0.00% | No change | 10,659 | $2K |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 4,500 | $1K |
| FNY Investment Advisers, LLC | 0.00% | New | 5,100 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +1375.2% | 3,629 | $835 |
| Group One Trading LLC | 0.00% | Reduce -56.0% | 3,355 | $771 |
| SBI Securities Co., Ltd. | 0.00% | — | 1,883 | $433 |
| Morgan Stanley | 0.00% | Reduce -29.6% | 1,684 | $387 |
| PNC Financial Services Group, Inc. | 0.00% | No change | 1,095 | $252 |
| JPMorgan Chase & Co. | 0.00% | No change | 549 | $127 |
| Wells Fargo & Company | 0.00% | No change | 454 | $104 |
| Bank of America Corp. | 0.00% | Reduce -69.9% | 212 | $48 |
| Osaic Holdings, Inc. | 0.00% | Reduce -89.0% | 113 | $24 |
| Activest Wealth Management | 0.00% | No change | 87 | $20 |
| Sound Income Strategies, LLC | 0.00% | No change | 76 | $17 |
| PSI Advisors, LLC | 0.00% | No change | 13 | $3 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 8 | $2 |
| Truvestments Capital LLC | 0.00% | New | 10 | $2 |
| FMR LLC | 0.00% | No change | 2 | $0 |
"% of holder's portfolio" is SYRS's weight in each manager's 13F, not the share of Syros Pharmaceuticals Inc. the manager owns.